CUE

Healthcare Biotechnology

Cue Biopharma, Inc.

$25.57

+0.77 +3.10% today

Price History

Not enough data

Key Stats

Market Cap

185.75M

Avg Volume

264,667

EPS

-$29.46

52W High

$45.50

52W Low

$4.98

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-53.27

P/B Ratio

57.85

P/S Ratio

4.93

EV/EBITDA

-1.76

EV/Revenue

4.55

Margins

Gross Margin (99.2%)

Operating Margin (1113.3%)

Net Margin 0.0%

EBITDA Margin (258.4%)

Growth & Returns

Revenue Growth (YoY)

166.7%

Return on Equity

(1603.5%)

Return on Assets

(172.7%)

Liquidity & Leverage

Current Ratio

1.25

Quick Ratio

1.07

Debt / Equity

1.33

Total Cash

17.41M

Total Debt

3.08M

About

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.